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Turner syndrome (TS) patients can be identified by short 
stature and gonadal dysgenesis.1 In addition to these 
features, characteristic facial and craniofacial morphology 
have been established. Most commonly reported craniofacial 
characteristics are reduced lengths of cranial base, maxilla 
and mandible, as well as flattened cranial base, maxillary and 
mandibular retrognathism and retroinclination. 2-7
ABSTRACT
Introduction: In addition to well-established physical characteristics, Turner syndrome patients have distinct craniofacial morphology. 
Since short stature is the most typical characteristic, Turner syndrome patients are commonly treated with growth hormone in order 
to increase final height. At the same time, growth hormone treatment was found to influence craniofacial growth and morphology 
in various groups of treated patients. Whereas craniofacial characteristics of Turner syndrome patients are well documented, 
comparatively little is known of craniofacial morphology of those who are treated with growth hormone.
Aim: The aim of this study was to investigate craniofacial morphology in Turner syndrome patients treated with growth hormone in 
comparison to healthy females.
Materials and methods: The cephalometric evaluation was conducted on twenty lateral cephalograms of Turner syndrome patients 
(13.53 ± 4.04 years) treated with growth hormone for at least one year (4.94 ± 1.92 years in average). As a control group, forty 
lateral cephalograms of healthy female controls, who matched Turner syndrome patients by chronological (11.80 ± 2.37 years) and 
skeletal age, were used. Eleven angular, seven linear measurements and six dimensional ratios were measured to describe craniofacial 
morphology.
Results: The results obtained for angular measurements, in cephalometric analyses for Turner syndrome patients treated with growth 
hormone, revealed bimaxillary retrognathism. The linear measurements indicated longer mandibular ramus, anterior cranial base 
and both anterior and posterior facial heights. However, posterior cranial base and maxilla were in proportion to the anterior 
cranial base, when comparing dimensional ratios. Anterior cranial base, maxilla and mandibular ramus were larger in proportion to 
mandibular body; as well as posterior facial height was when compared to anterior facial height.
Turner syndrome patients treated with growth hormone expressed distinct craniofacial morphology compared to controls. Apart 
from retrognathic maxilla and mandible, they exhibited overdeveloped mandibular ramus height and elongated facial heights.
Conclusions: The results from this study have shown that Turner syndrome patients treated with growth hormone expressed distinct 
craniofacial morphology compared to controls. These differences include retrognathic maxilla and mandible, overdeveloped 
mandibular ramus height and elongated facial heights. This specific craniofacial morphology was formed under combined influence 
of X chromosome deficiency and growth hormone therapy. 
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Chromosome imbalance, lack of X chromosome linked genes 
expression, growth hormone resistance and lack of estrogen 
should be taken into consideration when discussing these 
girls’ growth disturbances. The absence of X chromosome, 
which causes this syndrome, affects almost all structures of the 
craniofacial complex in terms of reducing their growth and 
altering growth direction.8,9 Additionally, haploinsufficiency 
of SHOX (short stature homeobox) gene, which is located 
in pseudoautosomal region 1 of X chromosome, influences 
skeletal and craniofacial growth and development.10 It is 
assumed that TS girls have short stature as a result of growth 
hormone or insulin-like growth factors resistance, even though 
they do not have classic growth hormone deficiency. 11 The lack 
of estrogen reduces speed of growth and skeletal maturation 
which is especially pronounced after the age of six or seven.11 
Growth disorders in TS girls, both skeletal and craniofacial, 
are complex and cannot be explained by the influence of any 
of these factors individually. Since short stature is the most 
common characteristic and evident repercussion of skeletal 
growth disorder in TS patients, they are routinely treated with 
growth hormone (GH). 12,13 GH therapy accelerates growth and 
improves their final body height up to 15 cm above predicted 
height. 14,15
Besides its positive effects on body height, GH seems to 
influence craniofacial growth.16-20 GH treatment was found 
to increase the length of maxilla and mandible, 18-21 as well 
as anterior and posterior facial heights 17-19,22 and cranial base 
length.17,21,23 Afore cited data are the results from studies that 
have investigated GH effects on craniofacial morphology in 
growth hormone deficient children, 16-18 children born too 
small for their gestational age 21,22 and children who have been 
subjected to whole body radiation. 20
As far as TS patients are concerned, most of the preceding 
studies have investigated craniofacial morphology in those who 
were not treated with GH. In these studies, distinct craniofacial 
morphology was established: flattened cranial base with 
reduced length, underdeveloped, retrognathic and retroinclined 
maxilla and mandible.2-7 Only a few studies have evaluated GH 
influence on craniofacial morphology in TS patients. 24-26 It was 
noticed that after two years of GH treatment both maxilla and 
mandible achieved average length, 24,25 their anteroposterior 
position did not improve, 24-26 while mandible was anteriorly 
rotated. 24,26 Taking into consideration these findings it could 
be expected that craniofacial morphology in TS patients who 
are treated with GH has certain distinct characteristics. 
Although craniofacial morphology in Turner syndrome 
patients is thoroughly described, data on those receiving 
growth hormone are still insufficient. The aim of this study 
was to investigate craniofacial morphology in Turner syndrome 
patients treated with growth hormone. The null hypothesis was 
that there are no differences between craniofacial morphology 
in Turner syndrome patients treated with growth hormone and 
healthy females.
MATERIALS AND METHODS
The Ethics Committee of School of Dental Medicine, University of 
Belgrade approved this study protocol (36/15). Informed consent 
was obtained from investigated individuals or their parents. 
The study group comprised of 20 lateral cephalograms of TS 
patients (13.53 ± 4.04 years old) who were treated with GH for 
at least one year (4.94 ± 1.92 years in average). All patients were 
treated with GH according to administration protocol at the 
Institute for Mother and Child Healthcare of Serbia “Dr. Vukan 
Čupić”. GH was administered as soon as height was lower 
than the tenth percentile of the normal female growth curve. 
Starting dose was 0.045-0.050 mg GH / kg of body weight per 
day which was adapted according to patient’s growth response. 
The duration of GH therapy was also determined according 
to patient’s height and growth response. The diagnosis was 
established using genetic karyotyping by routine chromosomal 
analysis performed on peripheral blood lymphocytes. The 
most common karyotype was 45,X (70%), followed by mosaic 
(30%) and isochromosome karyotype (10%). 
Forty lateral cephalograms of healthy females, matching TS 
patients by chronological (11.80 ± 2.37 years) and skeletal age, 
were included in control group. The records were obtained at 
the Department of Orthodontics, School of Dental Medicine 
in Belgrade.
The lateral cephalograms were taken under standardized 
conditions, with teeth in centric occlusion and head fixed in a 
cephalostat. All cephalograms were traced and analyzed by one 
investigator. A caliper was used to measure distances between 
reference points (marked in pencil on a mat acetate film) to 
the nearest millimeter. Angular measurements were measured 
to the nearest degree, using a protractor. In case of duplicated 
structure, reference point was marked at the midpoint. 
Figure 1. Cephalometric points and planes used in this study.
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The following cephalometric points and planes were used in 
this study (Figure 1): N, Nasion: the most anterior point of 
the frontonasal suture; S, Sella: the midpoint of the sella; Cd, 
Condylion: the most posterior superior point of the condyle; 
Ar, Articulare: a constructed point at the intersection of the 
images of the posterior margin of the ramus and the outer 
margin of the cranial base; Ba, Basion: lowest point on the 
anterior margin of the foramen magnum; Go, Gonion: a 
constructed point at the intersection of the ramus tangent line 
and mandibular plane; Me, Menton: the most inferior point of 
the outline of the symphysis; Pg, Pogonion: the most anterior 
point of the bony chin; B, Point B: the deepest point on the 
outer contour of the mandibular alveolar process; A, Point A: 
the deepest point on the outer contour of the maxillary alveolar 
process; Sna, Spina nasalis anterior: the most anterior point of 
the tip of the anterior nasal spine; Snp, Spina nasalis posterior: 
the intersection of the continuation of the anterior wall of 
the pterygomaxillary fissure and the nasal floor; NS, anterior 
cranial base: the line from nasion through sella; SpP, Spina 
planum: the line through spina nasalis anterior and posterior; 
MP, Mandibula planum: the tangent to the lower border of the 
mandible through menton.
Eleven angular measurements were used to describe 
anteroposterior (SNA, SNB, ANB) and vertical position of 
maxilla and mandible (NS/SpP, NS/MP, SpP/MP), as well as 
cranial base angle (NSBa) and angles of Bjork’s polygon (NSAr, 
SArGo, ArGoMe, sum of angles). Seven linear measurements 
were used to estimate the size of the maxilla (Snp - Sna), the 
mandibular body (Go - Pg) and ramus (Cd - Go), as well as 
the anterior and posterior cranial base (N - S, S - Ba) and 
facial heights (S - Go, N - Me). Six dimensional ratios were 
calculated to compare the lengths of maxilla, mandibular body 
and posterior cranial base to anterior cranial base (Snp-Sna/N 
- S, Go - Pg/N - S, S - Ba/N - S respectively) maxilla and 
mandibular ramus to mandibular body (Snp - Sna/Go - Pg, 
Cd - Go/Go - Pg) and posterior to anterior facial height (S - 
Go/N - Me).
The cephalometric measurements were performed twice on 
ten randomly selected radiographs, five from each group, in an 
interval of four weeks. In order to estimate the measurement 
error, Dahlberg’s formula was used √(∑d2/2N), where d is the 
difference between the two measurements and N is the number 
of cephalograms. The intra - individual error of measurement 
was generally small, did not exceed 0.8 degrees for the angular 
measurements and 0.3 mm for the linear measurements.
The Kolmogorov - Smirnov test confirmed normal distribution 
pattern of cephalometric measurements which allowed the use 
of parametric statistical tests. Independent samples t test was 
used to compare measurements between study and control 
group in order to establish weather differences were statistically 
significant. The Statistical Package for Social Sciences, version 18 
(SPSS inc.; Chicago, IL, USA) was used for statistical analysis.
RESULTS
The results obtained in cephalometric analyses of Turner 
syndrome patients treated with growth hormone and control 
are summarized in Table 1. All angular measurements, except 
for SNA and SNB angles, were similar in both groups. In TS 
patients treated with GH, both maxilla (SNA) and mandible 
(SNB) were significantly retropositioned, compared to control 
group (Figure 2). Some of the linear measurements (Cd - Go, 
N - S, S - Go, N - Me) were larger in examined group indicating 
longer mandibular ramus (Figure 3), anterior cranial base and 
Figure 2. Tracings of the Turner syndrome patients treated with growth 
hormone (red) and healthy controls (black) based on the mean cephalometric 
variables for each group, superimposed on the anterior cranial base (NS) and 
registered at the sella point (S).
Figure 3. Tracings of the Turner syndrome patients treated with growth 
hormone (red) and healthy controls (black) based on the mean cephalometric 
variables for each group, superimposed on the mandibular plane (MP).
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both anterior and posterior facial heights (Figure 2). However, 
when comparing dimensional ratios, we found that posterior 
cranial base and maxilla were in proportion to the anterior 
cranial base (S-Ba/N - S, Snp-Sna/N - S), while mandibular 
body was found to be smaller compared to anterior cranial base 
(Go - Pg/N - S) in TS patients compared to healthy controls. 
Both maxilla and mandibular ramus were larger in proportion 
to mandibular body (Snp - Sna/Go - Pg and Cd - Go/Go - Pg) as 
well as posterior facial height compared to anterior facial height 
(S - Go/N - Me) in study group.
DISCUSSION
According to the results obtained in this study, the null 
hypotheses was rejected. Turner syndrome patients treated with 
growth hormone exhibited aberrant craniofacial morphology 
when compared to healthy females. The differences were most 
pronounced in anteroposterior position of jaws, facial heights, 
mandibular ramus and anterior cranial base lengths. The X 
chromosome deficiency in combination with GH therapy effects 
led to this specific craniofacial morphology in TS patients.
All TS subjects included in this study were treated with GH for 
not less than one year, while some of them were treated for as 
long as seven years. Most of the included subjects started GH 
treatment before the age of seven. According to the results from 
previous studies, early initiation of treatment is necessary in order 
to have significant effects on craniofacial development.18,25,27 
Since GH therapy effects are age dependent, it could have been 
beneficial if the subjects were divided into age groups. Still, 
the number of investigated TS patients in subgroups would 
not have been sufficient for adequate statistical analyses. In 
the view of the fact that short stature was the main indication 
for GH therapy in TS patients included in this study, it was 
not possible to influence the age of treatment outset nor the 
duration of therapy. Both of these parameters were determined 
by the pediatric endocrinologist dependent on patients’ height 
and growth response.
Since craniofacial morphology did not differ significantly 
between patients with various karyotypes, 2,3,7,24 all karyotypes 
were included in this study. Even though 45,X TS patients 
had more variables differing from controls than other 
TS karyotypes, the only significant difference found was 
anteroposterior position of the mandible. 28 The karyotypes 
of TS patients selected for the study group were distributed 
somewhat differently compared to the average TS population. 
Monosomy of X chromosome was most frequent, similarly 
to an average TS population in Serbia. On the other hand, 
mosaic karyotypes were more frequent than isochromosomes, 
in contrast to what was expected. 29 It may be speculated that 
distribution of karyotypes did not alter the results in this 
study, since different karyotypes did not influence craniofacial 
morphology significantly.
Anteroposterior position of maxilla and mandible in Turner 
syndrome patients treated with growth hormone differed 
significantly from healthy controls. Both jaws were retrognathic, 
even though maxillary and mandibular body average length 
increased under the influence of GH therapy. These results 
are in accordance with previous studies that have also found 
retrognathic jaws 24-26 and increase in mandibular ramus 24-26 
and corpus lengths 25,26 in TS girls treated with GH. Bimaxillar 
retrognathism, also present in TS girls 2,3,5-7 and adult patients 4,8 
that were not treated with GH, used to be explained by flattened 
cranial base 3 and reduced lengths of maxilla and mandible. 2,8 
In TS patients treated with GH both jaws had average length, 
still their position was not ortognathic. On the other hand, the 
lack of X chromosome was proved to cause retrognathism 8,9 
which is present even prenatally in TS patients. 30 The results 
of this study suggest that retrognathic position of maxilla and 
mandible in TS patients, caused mostly by X chromosome 
deficiency, cannot be corrected by GH treatment.
In accordance with previous investigations, vertical position 
of maxilla and mandible did not differ between groups. The 
growth of mandibular ramus under the influence of GH 
treatment causes anterior rotation of mandible in TS patients, 24,26 
as well as in idiopathic short stature boys and GH deficient 
boys. 18 Similarly, in this study mandibular ramus height was 
found to be significantly larger in TS patients treated with 
GH compared to healthy controls and also overdeveloped in 
comparison to mandibular corpus length. However, even in TS 
patients naive to GH treatment ramus was found to be longer 
in proportion to corpus. 3,5 The fact that the vertical position 
of both jaws was similar between investigated groups in our 
study and that mandibular ramus height was larger in the 
study group, confirmed the earlier findings that GH therapy 
influences vertical position of jaws.
In contrast to the findings from previous studies, which found 
flattened cranial base angle and shorter posterior cranial base 
length in TS patients, 2,3,5-8,30 no significant differences were 
found between groups, excluding larger anterior cranial base 
in study group. Posterior to anterior cranial base ratio proved 
that in TS patients treated with GH, cranial base was normally 
developed. This finding can be explained by the results from 
clinical and experimental studies which found that GH has 
positive effects on enchondral ossification centers in the cranial 
base. 17,18,27 Additionally, the age of patients receiving GH 
has an impact on craniofacial growth, the effects being more 
pronounced in the younger patients. 18,27 The starting age of GH 
therapy, which was before the age of 7 in most of the patients 
in our study, contributed to normal cranial base development. 
Earlier studies of TS patients did not find significant 
differences when comparing annual changes of cranial base 
angle and lengths during GH therapy, 24,25 nevertheless growth 
rate and pattern were similar to healthy controls. 31 
The anterior cranial base was found to be longer in examined 
group, in spite of that the ratios imply that anterior cranial base 
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was proportionately developed when compared to posterior 
cranial base and maxillary length. Interestingly, mandibular 
corpus which was of average length in the examined group 
was found to be underdeveloped when compared to maxillary 
corpus and anterior cranial base length. These results indicate 
that mandibular corpus, which was significantly shorter in TS 
patients naive to GH treatment, 2,3,5-7 could not keep up with 
maxillary corpus and anterior cranial base length, despite the 
fact that it increased the length in patients treated with GH. 
On the other hand, mandibular ramus was overgrown in 
comparison to mandibular corpus most probably due to bone 
apposition on secondary mandibular condylar cartilage. 32 
Increased length of mandibular ramus, in combination with 
the average length of posterior cranial base, was considered to 
contribute to increased facial heights in study group. 18,19,21 The 
ratio between posterior and anterior facial height indicated that 
the effects were more pronounced on posterior facial height. 
The results from this study have shown that Turner syndrome 
patients treated with growth hormone expressed distinct 
craniofacial morphology compared to healthy controls. 
These differences include retrognathic maxilla and mandible, 
overdeveloped mandibular ramus height and elongated facial 
heights. This specific craniofacial morphology was formed 
under combined influence of X chromosome deficiency and 
growth hormone therapy. 
Further carefully designed studies are necessary to explore 
possibility of changing craniofacial morphology in Turner 
syndrome patients by including orthodontic growth 
modification treatment.
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Table 1. The results obtained in cephalometric analyses of Turner syndrome patients treated with growth hormone and healthy females
TS patients receiving GH (n=20) Control group of healthy girls (n=40) T-test for independent samplest
Mean SD SE Mean SD SE P value for independent samples
Angular measurements
SNA (º) 78.09 4.83 1.08 81.57 4.33 0.68 .010*
SNB (º) 75.01 4.18 0.94 78.04 4.28 0.68 .012*
ANB (º) 3.09 1.23 0.28 3.53 2.39 0.38 .355
NS/SpP (º) 9.34 4.36 0.98 8.43 3.82 0.60 .433
NS/MP (º) 31.99 6.58 1.47 33.59 6.16 0.97 .373
SpP/MP (º) 22.65 6.05 1.35 24.85 6.74 1.07 .209
NSBa (º) 132.02 5.65 1.26 130.77 5.50 0.87 .420
NSAr (º) 125.71 6.80 1.52 122.75 5.38 0.85 .099
SArGo (º) 143.35 8.36 1.87 145.15 5.74 0.91 .395
ArGoMe (º) 123.22 9.26 2.07 125.72 7.43 1.17 .302
Sum of angles (º) 392.24 6.56 1.47 393.62 6.13 0.97 .438
Linear measurements
Snp-Sna (mm) 51.78 4.41 0.99 49.63 3.24 0.51 .063
Go-Pg (mm) 67.67 5.37 1.20 67.62 4.57 0.72 .972
Cd-Go (mm) 55.77 5.86 1.31 51.26 5.51 0.87 .007*
N-S (mm) 68.05 4.77 1.07 64.97 3.36 0.53 .015*
S-Ba (mm) 43.92 5.48 1.23 42.55 2.96 0.47 .307
S-Go (mm) 77.68 8.42 1.88 69.60 4.92 0.78 .001*
N-Me (mm) 113.46 11.29 2.52 106.41 6.96 1.10 .017*
Dimensional ratios
Snp-Sna/N-S (%) 76.09 4.67 1.04 76.43 3.84 0.61 .783
Snp-Sna/Go-Pg (%) 76.66 5.42 1.21 73.57 5.09 0.80 .041*
Go-Pg/N-S (%) 99.45 5.17 1.16 104.20 6.68 1.06 .004*
Cd-Go/Go-Pg (%) 82.81 7.57 1.69 75.85 6.96 1.10 .001*
S-Ba/N-S (%) 64.81 9.15 2.05 65.57 4.47 0.71 .727
S-Go/N-Me (%) 68.50 3.67 0.82 65.52 4.21 0.66 .007*
Standard deviation (SD); Standard error (SE).*P < 0.05.
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